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Abstract 
Background: Patients with inactivating mutations in kisspeptin signalling are infertile. 
Kisspeptin-54, the major circulating isoform of kisspeptin in humans, potently 
stimulates reproductive hormone secretion in humans. Animal studies suggest that 
kisspeptin is involved in the generation of the luteinising hormone surge, which is 
required for ovulation. I hypothesised that kisspeptin-54 could be a novel method 
used to trigger egg maturation in women undergoing in vitro fertilisation therapy. 
Methods: This was a proof of concept study. Following superovulation with follicle 
stimulating hormone, and gonadotrophin releasing hormone antagonist administration 
to prevent premature ovulation, 53 women were administered a single subcutaneous 
injection of kisspeptin-54 (1.6nmol/kg, n=2; 3.2nmol/kg, n=3; 6.4nmol/kg, n=24; 
12.8nmol/kg, n=24) to induce a luteinising hormone surge and egg maturation. Eggs 
were retrieved transvaginally 36h after kisspeptin injection, assessed for maturation 
(primary outcome), and fertilised by intracytoplasmic sperm injection with 
subsequent transfer of one or two embryos.  
Results: Overall, egg maturation was observed in 96% (51/53) of patients. 
Fertilisation of eggs and transfer of embryos to the uterus occurred in 92% (49/53) of 
patients. Biochemical and clinical pregnancy rates were 40% (21/53) and 23% 
(12/53), respectively.  
Conclusion: This study demonstrates that a single injection of kisspeptin-54 can 
induce high rates of egg maturation in women with sub-fertility undergoing in vitro 
fertilisation therapy. Subsequent fertilisation of eggs matured following kisspeptin-54 
administration and transfer of resulting embryos can lead to successful human 
pregnancy.  
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Infertility 
Infertility is defined by the Human Fertilisation and Embryology Authority (HFEA) 
as an inability of a couple to conceive after two years of regular sexual intercourse. 
The National Institute for Clinical Excellence (NICE) estimates that one in six 
couples in the UK have difficulty conceiving. Infertility constitutes, therefore, a 
significant health problem, which can have substantial medical, psychological and 
financial implications for women and couples who find it difficult to conceive. IVF 
has now become an important aspect of assisted conception treatment for such 
couples. 
 
IVF treatment  
Since Louise Brown, the first IVF baby, was born in 1978, the science of in vitro 
fertilisation (IVF) has changed considerably. IVF treatment was initially indicated for 
patients with tubal blockage, but it has since been established as the treatment of 
choice for many couples with unexplained infertility, male infertility, polycystic 
ovarian syndrome and endometriosis.  
 
IVF treatment consists of  seven, sequential steps, which occur continuously during a 
single menstrual cycle: 
1. Controlled ovarian stimulation. Exogenous hormones are administered to the 
patients to stimulate the ovaries such that multiple follicles containing oocytes 
develop simultaneously. Conversely during a physiological menstrual cycle, 
the ovaries typically produce only one follicle containing one oocyte. 
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2. Preventing a premature LH surge.  A premature surge of luteinising hormone (LH) 
could lead to premature ovulation and to a decrease in the number of eggs, 
which could then be retrieved. The use of GnRH analogues during the phase 
of stimulation of the ovaries can prevent the LH surge through reversible 
blockade of the pituitary GnRH receptors. 
3. Triggering oocyte maturation. In order for oocytes to become mature and gain the 
competence for fertilisation by sperm, LH exposure is required. This can be 
achieved through the bolus administration of pharmacological agents such as 
hCG, which simulates the effects of the natural mid-cycle LH surge.  
4. Oocyte retrieval. The oocytes are usually retrieved from the ovaries in an outpatient 
setting. The operating doctor passes a needle through the vaginal wall under 
ultrasound guidance and aspirates the fluid from the follicles to retrieve the 
egg. 
5. In vitro fertilisation. The collected oocytes are then placed adjacent to sperm in 
laboratory petri dish for in vitro fertilisation (IVF). Alternatively the 
embryologist may perform a procedure called intracytoplasmic sperm 
injection (ICSI), during which a single spermatozoon is injected directly into 
the oocyte for fertilisation. 
6. Embryo transfer. The cultured embryos are subsequently replaced in the uterus 
using a specially designed catheter under ultrasonographic guidance. This 
should lead to pregnancy if the embryo successfully implants into the uterus. 
7. Luteal phase support: After the embryos have been replaced in the uterus, the 
patients are given exogenous progestogens to enhance the luteal phase and 
promote the implantation of the embryos. 
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 I will describe each of these sections of IVF treatment below. 
1. Controlled ovarian hyperstimulation.  
The aim of the initial phase of IVF treatment is to promote multi-follicular growth 
via pharmacological ovarian stimulation. To achieve this, human menopausal 
gonadotrophins (hMGs), which are manufactured from urine of menopausal 
women, or recombinant FSH (rFSH) are used. Their defining difference is that 
hMG exerts a dual FSH and LH activity, unlike rFSH, which does not exert any 
LH activity (van Wely et al, 2011).  
 
2. Preventing a premature LH surge 
(a) preventing a premature LH surge using GnRH agonists  
During in vitro fertilisation (IVF) cycles, the general aim is to improve success rates 
by producing a sufficient number of embryos. During the initial stage of controlled 
ovarian stimulation, patients are administered individualised doses of gonadotrophins 
in order to induce the growth of multiple follicles. However, a premature LH surge 
constitutes a significant risk, which could lead to premature ovulation and to a 
decrease in the number of oocytes,which can therefore be retrieved. The use of GnRH 
agonists during the phase of controlled stimulation has allowed for prevention of a 
premature LH surge through downregulation of the GnRH receptors of the pituitary 
gland (Maheshwari 2011). The positive effect of the use of GnRH agonists in IVF 
cycles was first demonstrated by researchers in Hammersmith Hospital. Namely 
Rutherford et al (1988) first reported that the use of buserelin to down-regulate 
pituitary receptors prior to commencing ovarian stimulation with urinary 
gonadotrophins was associated with significantly improved numbers of recovered 
oocytes, obtained embryos and clinical pregnancies compared to the usual –at the 
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time- regime of clomiphene citrate and urinary gonadotrophins. 
 
More specifically, the GnRH agonists bind to their pituitary receptors and lead to an 
initial release of high amounts of FSH and LH, also known as the flare-up effect. 
After prolonged administration, the GnRH agonist / receptor complex is internalised 
in the pituitary gonadotroph cell and a down-regulation of GnRH receptors occurs. 
This desensitisation of the pituitary gland usually occurs after at least two weeks of 
GnRH agonist treatment. The return to normal function of the GnRH receptor after 
cessation of the GnRH agonist administration is gradual, which may also have 
implications for the luteal phase of an IVF cycle.  
 
During a long GnRH agonist protocol, GnRHa is administered for a minimum of 14 
days to achieve pituitary down-regulation before the gonadotrophin is commenced 
(Maheshwari et al, 2011). Two distinct long protocols exist: in the luteal phase (or 
day 21) long protocol the GnRHa is commenced from day 21 (mid-luteal phase) of 
the previous cycle. In comparison during a follicular phase protocol, GnRHa is 
commenced on day 2 of the menstrual cycle. Concurrent GnRHa and gonadotrophins 
administration continues until an adequate number of stimulated follicles are present, 
at which stage a bolus injection of hCG is administered to induce oocyte maturation. 
When comparing the two long GnRHa protocols, Kondaveeti-Gordon et al (1996) 
reported no significant difference in pregnancy rates, although Jenkins et al (1996) 
reported that the follicular phase long protocol was associated with a higher risk of 
functional cysts, which can cause significant disruption in the planning of an IVF 
cycle. 
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(b) Preventing a  premature LH surge using GnRH antagonists 
The long GnRHa protocol appears to be an effective method of ovarian stimulation in 
IVF cycles and has played a pivotal part in the reduction of the premature surge of 
LH, which would lead to IVF cycle cancellations. On the other hand the long protocol 
requires a minimum of 2 weeks to induce ovarian desensitisation. This can have a 
significant impact to patients and increase the psychological burden associated with 
fertility treatment. It may also have a relatively high cost in terms of finances and 
time, due to an increase in for gonadotrophin requirement and the subsequent need for 
frequent ultrasound assessments (Oliviennes et al, 1994). 
 
GnRH antagonists have now been developed as the alternative option for the 
prevention of a premature LH surge during IVF treatment. GnRH antagonists can 
prevent a premature LH surge during the phase of ovarian stimulation as well as  the 
notable hypo-oestrogenic side effects or long period of administration associated with 
the use of GnRH agonists (Al Inany et al, 2011). GnRH antagonists prevent 
endogenous GnRH from stimulating the pituitary gonadotroph cells through the 
competitive blockade of the GnRH receptors. This blockade of the GnRH receptors of 
the pituitary gland leads to a cessation of FSH and LH secretion from the pituitary 
gonadotroph cells. As a result, the main advantage of using GnRH antagonists to 
prevent premature LH surge is the rapidity of onset of action and the rapidity of 
offset, due to the fact that they are competitive antagonists and can therefore be 
displaced from the receptor by a GnRH agonist. The use of GnRH antagonists thus 
allows for the use of a GnRH agonist to trigger oocyte maturation.   
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The GnRH antagonist (ganirelix or cetrorelix) is administered in daily 0.25mg doses, 
from the sixth day of controlled ovarian stimulation onwards (Huirne et al, 2007). A 
further variation was introduced to reduce the required number of GnRH antagonist 
doses by the use of flexible protocols. In a flexible protocol, the GnRH antagonist is 
commenced when the largest ovarian follicles reach a size >14-16 mm in mean 
diameter. 
 A meta-analysis to compare the fixed and flexible GnRH antagonist protocols, has 
demonstrated no statistically significant difference in pregnancy rates, although there 
appeared to be a trend towards higher pregnancy rates when the fixed protocol was 
used (Al Inany et al, 2005). On the other hand, the flexible protocol was associated 
with a statistically significant decrease in the number of GnRH antagonist doses and 
the total amount of required gonadotrophins used. 
A prerequisite for the GnRH antagonist protocol to commence is the occurrence of 
spontaneous menses, as the phase of controlled ovarian stimulation generally 
commences on day 2 of the menstrual cycle.  This may pose various difficulties in the 
scheduling of the IVF treatment to meet the organisational needs of the patient and 
the IVF unit with subsequent practical and financial implications. Oral contraceptive 
pill pretreatment has been used to counter this problem. The timing of the withdrawal 
bleed after the contraceptive pill pretreatment can be manipulated in GnRH antagonist 
cycles and can help with the scheduling of the oocyte retrieval to the convenience of 
both the patient and the physician (Griesinger et al, 2008).  
 
The initial results of randomised studies and meta-analyses (Al Inany et al, 2002) 
comparing GnRH agonist and antagonist protocols identified a 5% absolute reduction 
in clinical pregnancies associated with the antagonist protocol. This difference in 
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pregnancy rates was also demonstrated after the analysis of the results of a large 
German national IVF database and –as a result, the GnRH antagonist approach 
became the second choice for a large number of clinicians (Griesinger et al, 2005). 
These studies comparing the two suppression protocols employed hCG as the oocyte 
maturation trigger. By contrast the GnRH antagonist protocol was consistently 
associated with a reduced risk of ovarian hyperstimulation syndrome (OR 0.46, 95% 
CI 0.26-0.82) (Al Inany et al, 2001; Al Inany et al, 2006).  
 
Conversely the most recent systematic review and meta-analysis by the same authors 
(Al Inany et al, 2011) failed to identify any significant differences live birth rates 
when GnRH antagonist and GnRH agonist protocols were compared (OR 0.86, 95% 
CI 0.72-1.02). With regards to the safety during IVF treatment, GnRH antagonists 
continued to result in a significant reduction in the incidence of OHSS. These changes 
in the results of the most recent meta-analysis can potentially be attributed to more 
appropriate patient selection and IVF protocol allocation. In other words the improved 
learning curve and further experience with the use of GnRH antagonist protocols may 
have led to these favourable outcomes. 
 
 
3. Triggering oocyte maturation 
(a) hCG triggering of final oocyte maturation 
During a natural cycle, the mid-cycle surge of pituitary LH (and FSH) secretion 
induces ovulation. hCG shares the same alpha subunit and 81% of the amino acids of 
the beta subunit of LH. Both LH and hCG bind to the same receptor, which was first 
described by Kessler et al in 1979. Exogenous urinary hCG (at doses of 5000–10,000 
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IU) has been successfully introduced to simulate the natural LH surge and lead to 
oocyte maturation. The use of recombinant hCG has now become routine practice. 
Indeed in a randomised controlled trial by Papanikolaou et al (2010), patients were 
randomized to recombinant hCG (250 µg) or urinary-derived hCG (10,000 IU) to 
induce oocyte maturation. The pregnancy rate was significantly  improved with 
recombinant hCG compared to urinary hCG.  
 
Notably hCG has a significantly longer half-life than LH and will provide support to 
the multiple corpora lutea for seven to ten days, after which time hCG is cleared from 
circulation (Damewood et al., 1989; Mannaerts et al., 1998). Importantly the longer 
half-life of hCG in comparison to endogenous LH also results in a prolonged 
luteotrophic effect (promotion of multiple corpora lutea) and elevated serum 
oestradiol and progesterone levels during the luteal phase (Itskovitz et al., 1991), 
which has been shown associated with improved pregnancy rates, but also an 
increased risk of ovarian hyperstimulation syndrome (Haning et al., 1985). As a result 
alternative trigger agents have been investigated and developed because of this 
complication associated with the use of hCG.  
 
(b) GnRH agonist triggering of final oocyte maturation 
GnRH agonists can also promote oocyte maturation by inducing a surge in 
gonadotrophon secretion (flare-up effect), similar to the surge that occurs in the 
physiological cycle (Gonen et al., 1990; Itskovitz et al., 1991). However, when a 
GnRH agonist is used to down-regulate the pituitary GnRH receptors prior to 
commencing the phase of ovarian stimulation (Porter et al., 1984), the use of GnRHa 
for triggering oocyte maturation would not be applicable, as the GnRH receptor is still 
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down-regulated and non-responsive. Since the introduction of GnRH antagonists for 
the prevention of a premature LH surge during IVF treatment (Albano et al., 1997; 
Itskovitz-Eldor et al., 1998; Borm and Mannaerts, 2000;), it has become possible to 
induce oocyte maturation with a bolus dose of a GnRH agonist as an alternative to 
HCG. The GnRH agonist displaces the antagonist from the pituitary GnRH receptor 
and thus leads to a surge of endogenous gonadotrophins (LH and FSH).  
 
The GnRH agonist-induced surge of FSH and LH bears differences to the surge in 
gonadotrophins, which occurs in a physiological menstrual cycle. Specifically the 
physiological cycle surge of LH appears to have three sequential phases: a phase of 
rapid ascent with a duration of fourteen hours, a plateau with a duration of fourteen 
hours and a descending phase lasting twenty hours, such that the total duration is 48 
hours (Hoff et al., 1983). In comparison, the GnRH agonist-induced LH surge 
consists of two phases; a short ascending phase lasting >4 hours and a long 
descending phase lasting >20 hours and has a total duration between 24 to 36 hours 
(Itskovitz et al., 1991). This difference results in a significant reduction in the amount 
of released pituitary gonadotrophins when a GnRH agonist is used as the trigger of 
oocyte maturation when compared with the natural menstrual cycle (Gonen et al., 
1990; Itskovitz et al., 1991). As a result, GnRH agonist trigger has been associated 
with a deficient luteal phase and thus lower pregnancy rates (Balasch et al., 1995; 
Segal and Casper, 1992). To overcome the deficient luteal phase in IVF cycles, 
modified luteal phase support is used in IVF cycles to improve the pregnancy 
outcomes following GnRH agonist triggers (Humaidan et al., 2010).  
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Despite this, the use of a GnRH agonist trigger has significant safety advantages 
compared to hCG triggering, namely a significant reduction in and in some studies the 
complete prevention of ovarian hyperstimulation syndrome (Kol and Itskovitz-Eldor, 
2000; Kol, 2004; Orvieto, 2005). In addition, the use of a GnRH agonist trigger has 
been shown to result in a larger number of retrieved, mature, metaphase II (MII) 
oocytes when compared with an hCG trigger (Humaidan et al., 2005; Imoedemhe et 
al., 1991; Oktay et al., 2010). This particular finding could partly be attributed to the 
endogenous FSH surge, which occurs concurrently with the LH surge when a GnRH 
agonist trigger is used (Kol and Humaidan, 2010). In contrast an increase in FSH does 
not occur when hCG is used as a trigger of oocyte maturation. Theoretically the 
endogenous, concurrent surge in FSH can lead to oocyte nuclear maturation, through 
resumption of the second meiotic division and promote the formation of LH receptors 
in the luteinising, granulosa cells, thus benefiting the function of the multiple corpora 
lutea (Eppig, 1979; Stickland and Beers, 1976; Yding Andersen, 2002; Yding 
Andersen et al., 1999; Zelinski-Wooten et al., 1995). 
 
4. Oocyte retrieval 
Under transvaginal ultrasound guidance, the operating doctor inserts a long needle 
through the lateral fornix of the vaginal wall directly into an ovarian follicle, taking 
care not to injure any structures between the point of insertion of the needle into 
vaginal wall and the ipsilateral ovary. The proximal end of the needle is attached to a 
gentle suction apparatus. After each follicle is penetrated, gentle suction of 150mmHg 
is applied to aspirate the follicular fluid and with it the oocyte surrounded by 
granulosa cells. The follicular fluid is delivered directly to the embryologist in the 
laboratory, who will subsequently identify and quantify the collected oocytes. Once 
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all the accessible ovarian follicles have been aspirated from the ipsilateral ovary, the 
needle is withdrawn from the lateral fornix, and the procedure is repeated at the 
contralateral ovary. The procedure usually lasts from 20–40 minutes. 
 
5. In vitro fertilisation and  ICSI 
During routine IVF each egg is transferred in a culture droplet containing motile 
sperm at a concentration of 100 000 per ml. A single sperm will then spontaneously 
bind to and penetrate the zona pellucida of the egg to achieve fertilisation.   
In contrast, ICSI involves the injection of one (single) motile spermatozoon directly 
into the cytoplasm of the oocyte (ooplasm) (Figure 1.1). ICSI is often recommended 
when the male partner has a reduced sperm count; if sperm demonstrates poor 
morphology and/or poor motility and/or low concentration; if there was failed 
fertilisation or a low fertilisation rate at previous in vitro fertilisation (IVF) cycles. 
 
Figure 1.1. Intracytoplasmic sperm injection procedure. The polar body is visible at 6 o’clock, the 
micro-injector is seen at 3 o’clock and the end of the holding pipette at 9 o’clock. (Courtesy of IVF 
Hammersmith, Imperial College Healthcare NHS Trust) 
6. Embryo development and transfer 
The oocytes are assessed for fertilisation 16-18 hours after the ICSI procedure has 
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taken place. The oocytes are considered as fertilised when two clearly identifiable 
pronuclei are visible in the ooplasm (2-PN stage). The female pronucleus is a 
vesicular nucleus, which contains the haploid copy of the female chromosomes and 
forms in the oocyte immediately after entry of the spermatozoon. The spermatozoon 
forms the male pronucleus; which contains the haploid copy of the male 
chromosomes, after its tail detaches and degenerates. 
The 2-PN oocytes will enter the cleavage stage, which results in embryos with 
multiple cells (blastomeres). Normal, good-quality embryos enter the four-cell stage 
on day 2 and the 8-cell stage on day 3 (Figure 1.2). At that point, the number and size 
of blastomeres along with the presence of anucleate fragments is recorded.  Given that 
the embryonic genome becomes fully activated at the 8-cell stage, it would be 
preferable to use embryos that have undergone this transition from the maternal to the  
 
 
Figure 1.2. Day 3 embryo (8-cell stage). Blastomeres appear similar in size without fragmented 
components. 
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Figure 1.3. Day 4 embryo (morula). The blastomeres have undergone full compaction (16-32- cell 
stage) 
 
 
 
Figure 1.4. Day 5 embryo (blastocyst). The inner cell mass (ICM) is easily discernible at 7 o’clock and 
the trophoectoderm can be seen as a layer of cells throughout the periphery of the embryo. 
(Images are a courtesy of the IVF Hammersmith, Imperial College Healthcare NHS Trust) 
 
 
embryonic genome (Braude et al, 1988). This would potentially allow the 
identification of the embryos with the optimal potential for development. As a result, 
when feasible, embryos are allowed to progress to day 5 before transfer. Following a 
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full compaction of the embryonic cells on day 4 (morula stage) (Figure 1.3), an 
embryonic cyst gradually appears (blastocoele) (Figure 1.4). The blastocoele will 
separate the embryonic components to the inner cell mass (embryoblast) and the 
trophoectoderm which will subsequently form the placenta. 
 
The decision on which of the embryos are more suitable to return to the uterus for 
implantation depends on a grading system, which is based on morphological criteria 
(Table 1.1). 
Similar pregnancy outcome have been achieved following the transfer of a single 
blastocyst compared to two blastocysts (Criniti et al, 2005). A statistically significant 
increase in biochemical pregnancy (confirmed by the presence of a positive 
pregnancy test) (OR 1.45, 95% CI 1.03–2.04) and clinical pregnancy rates (defined by 
the presence of an active fetal heartbeat at the 6th gestational week ultrasound) (OR 
1.63, 95% CI 1.12–2.35) was shown a single blastocyst transfer compared with the 
transfer of a single cleavage stage (day 3) embryo in patients aged less than 36 years 
old (Papanikolaou et al, 2006;  Zech et al, 2007). 
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Table 1.1. Embryo Morphology Scheme for Day 3 and Day 5 embryos 
7. Luteal phase in IVF 
During the luteal phase of a natural cycle a corpus luteum is formed.  This produces 
progesterone and oestrogen, which are vital to maintain pregnancy. In a natural 
menstrual cycle, pituitary LH secretion maintains the corpus luteum. Progesterone is 
pivotal during the endometrial secretory phase, which is characterised by the 
thickening of the endometrial glands and increased vascularisation to promote 
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implantation. Following implantation, the developing embryo forms an inner cell 
mass, the embryoblast, and an outer cell mass, the trophoblast. The trophoblast, which 
will eventually form the placenta, produces human chorionic gonadotrophin (hCG) 
immediately after implantation. hCG is able to bind to and activate the LH receptor 
and hence maintain the corpus luteum (Penzias et al, 2002, Pabuccu et al, 2005). 
 
The luteal phase of IVF cycles is known to be deficient (Humaidan et al, 2012). The 
aetiology behind luteal phase deficiency of IVF treatment cycles is attributed to the 
high, circulating steroid levels (Fatemi et al, 2009) produced from the multiple 
corpora lutea, compared to the single corpus luteum formed in a natural cycle. The 
increase in oestrogen and progesterone levels then leads to suppression of the 
pituitary gland gonadotrophin secretion (negative feedback effect). Pituitary LH 
secretion is vital to maintain the corpus luteum. Hence during an IVF cycle where 
pituitary LH is suppressed, this results in premature breakdown of the corpus luteum 
which is termed luteolysis. Premature luteolysis, is associated with particularly poor 
pregnancy rates following IVF treatment (Van der Linden et al, 2011). To prevent 
premature luteolysis, various luteal phase support protocols have been described, but 
practice still varies considerably throughout the world (Fatemi et al, 2009). Luteal 
phase support (LPS) methods include the administration of hCG (Nosarska et al, 
2005) or progesterone via the oral (Chakravarty et al, 2005), vaginal (Zarutskie et al, 
2009), rectal (Simunic et al, 2007) or intramuscular route (Leeton et al, 1985). All 
meta-analyses and systematic reviews performed to date have demonstrated that 
progesterone administration via the intramuscular, vaginal or rectal routes would give 
comparable pregnancy rates in IVF treatment cycles when hCG was used as oocyte 
maturation trigger (Fatemi et al, 2009, Van der Linden et al, 2011, Tay et al, 2005). 
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Conversely, natural  micronised progesterone administered orally has not be shown to 
be efficient for luteal phase support due to its reduced bioavailability, since it is 
naturally subjected to first-pass hepatic metabolism (Fatemi et al, 2009). 
 
The addition of oestrogen to the progesterone for luteal phase support has been 
suggested as a means of improving implantation and pregnancy rates after IVF 
(Shahara et al, 1999). This has been hypothesised to be potentially beneficial based on 
the fact that during a natural cycle, the corpus luteum produces both oestrogen and 
progesterone. When progesterone-only luteal phase support is used, lower mid-luteal 
oestradiol concentrations could result in decreased pregnancy rates (Shahara et al, 
1999). However systematic reviews and meta-analysis have not demonstrated that the 
addition of oestrogen to progesterone-only luteal phase support protocols improves 
live birth rates in GnRH agonist and GnRH antagonist cycles (Van der Linden et al, 
2011, Jee et al, 2010, Kolibianakis et al, 2008).  
 
hCG has also been administered as an alternative option to progesterone for luteal 
phase support (LPS). A systematic review and meta-analysis of eighteen trials 
(Nosarka et al. 2005) demonstrated that hCG-based LPS appeared to be superior when 
compared with progesterone-based LPS (Nosarka et al, 2005). On the other hand, 
hCG-based LPS was also associated with a significant increase in ovarian 
hyperstimulation syndrome (Fatemi et al, 2007). Therefore, due to this risk, luteal 
phase support with hCG should be reserved for patients who are not at risk of ovarian 
hyperstimulation syndrome. hCG for LPS should not be used for patients at high risk 
of OHSS (e.g. polycystic ovarian syndrome, previous history of OHSS) (Van der 
Linden et al, 2011). 
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Ovarian hyperstimulation syndrome 
A better understanding of the reproductive endocrinology aspects behind IVF has led 
to an improvement in pregnancy outcomes and has allowed IVF to become the 
mainstay of fertility treatment worldwide. The improvement in success rates, 
however, has come at the cost of new complications such as ovarian hyperstimulation 
syndrome (OHSS). Ovarian hyperstimulation syndrome can be associated with severe 
morbidity and even rare cases of mortality have been reported. It constitutes an 
iatrogenic complication, which arises secondary to ovarian stimulation, and appears to 
be solely encountered in patients undergoing IVF treatment.  
 
Ovarian hyperstimulation syndrome (OHSS) is characterised by an excessive ovarian 
response to the administration of exogenous gonadotrophins. OHSS is typically only 
associated with ovarian stimulation with gonadotrophins in IVF cycles.  
 
OHSS symptomatology resolves spontaneously if conception does not occur, but may 
persist for many weeks when implantation of an embryo is successful and pregnancy 
occurs due to the endogenous production of HCG. OHSS encompasses a broad 
spectrum of symptoms, which range from mild abdominal distension to severe multi-
system disease requiring intensive care support.  
 
Pathophysiology 
The use of exogenous hCG to trigger oocyte maturation in IVF cycles is pivotal in the 
pathophysiology of ovarian hyperstimulation syndrome. hCG directly promotes the 
production of vascular endothelial growth factor (VEGF) by endothelial cells. A 
variety of cytokines have also been identified as mediators in the pathophysiology 
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process of OHSS, which include interleukin-1b (IL-1b), interleukin-6 (IL-6) 
angiotensin II, insulin-like growth factor 1 (IGF-1), epidermal growth factor (EGF), 
transforming growth factors (TGF) A and B and platelet-derived growth factor 
(PDGF), (Geva et al, 2000; Whelan et al, 2000; Warren et al, 1996; Ferrara et al, 
1997). 
 
The principal pathophysiology of OHSS is an increase in capillary permeability, 
which results in a fluid shift from the intravascular compartment to the third space 
(Tollan et al, 1990, Goldmann et al, 1995). Certain mechanisms have been implicated 
in this process and include the increased exudation of fluid from the expanded ovarian 
surface (Bergh et al, 1992, Koninckx et al 1980a, Koninckx et al, 1980b), increased 
levels of prorenin and renin in follicular fluid (Sealey et al, 1985, Donnez et al, 1982) 
as well as angiotensin-mediated alterations in capillary permeability (Derkx et al, 
1987, Lightman et al, 1987). 
 
A key factor in the pathophysiology of the syndrome is the increased release of VEGF 
(Geva et al, 2000). VEGF is an angiogenic cytokine, which can potently stimulate the 
vascular endothelium and appears to play a pivotal part in follicular development and 
corpus luteum secretion. VEGF levels have been shown to correlate with the severity 
of the syndrome (Levin et al, 1998) and recombinant VEGF administration can 
produce similar sequelae to OHSS, which can be reversed with the use of a specific 
antiserum (McClure et al, 1994; Neulen et al, 1995).  
 
 
 
 
 
 
 
 
34 
Risk factors 
Ovarian hyperstimulation syndrome has been independently linked to certain risk 
factors which are described in Table 1.2 (Whelan et al, 2000; Navot et al, 1988; 
Delvigne et al, 1993; McDougall et al, 1992; Buyalos et al, 1996; Forman et al, 1990; 
Mizunuma et al, 1992; Mordel et al, 1993; Haning et al, 1983). 
 
 
 
 
 
 
 
 
 
 
Table 1.2. Independent risk factors associated with ovarian hyperstimulation syndrome 
 
The risk of OHSS is also related to the number of developing follicles during the 
phase of ovarian stimulation (Enskog et al, 1999), and the number of retrieved 
oocytes at the end of the cycle (McDougall et al, 1992). The risk also appears to 
increase when higher hCG doses are administered to induce oocyte maturation. OHSS 
manifestation becomes less likely when progesterone-based luteal phase support is 
used instead of hCG (Foreman et al 1990). As expected, once implantation has been 
successful, increasing levels of hCG will also increase the duration and severity of the 
OHSS symptomatology. 
 
Risk factors for OHSS 
Young maternal age 
Low body mass index (BMI) 
Polycystic ovary syndrome  
High doses of exogenous FSH during ovarian stimulation 
Elevated serum oestradiol during ovarian stimulation 
Previous history of OHSS 
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Clinical Features 
According to its traditional classification (Golan et al, 1989), OHSS may manifest as 
mild, moderate, or severe. Similarly the Royal College of Obstetricians and 
Gynaecologists has employed the following classification: 
 
The clinical features of OHSS, however, are expressed in the form of a continuous 
spectrum, which may render strict classification impossible. The mild form of the 
syndrome is relatively common and includes abdominal distension, transient 
abdominal pain and diarrhoea, which are encountered in up to 33% of all patients 
undergoing IVF treatment. The onset of symptoms typically occurs after oocyte 
retrieval, but may be delayed and manifest only after the embryo transfer has 
occurred. The manifestations of moderate OHSS include the presence of ascites, 
which may be diagnosed clinically by the increase in abdominal girth or after 
ultrasound examination. The progression to the severe form of the syndrome may be 
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characterised by the presence of tense ascites, tachycardia, tachypnoea, orthostatic 
hypotension, hydrothorax and oliguria. 
 
Hypotension results from the fluid shift towards the third space and the contraction of 
the vascular volume, whilst the subsequent oliguria is a sequel of decreased vascular 
volume and increase intra-abdominal pressure. The risk of venous thromboembolism 
increases as a result of haemoconcentration and relevant inactivity due to abdominal 
distension. Finally the life-threatening or critical form of OHSS includes acute renal 
failure, adult respiratory distress syndrome (ARDS) and venous thromboembolism 
(Whelan et al, 2000, Zosmer at al, 1987, Abramov et al, 1999). 
 
Management of OHSS 
Outpatient Management 
The management of patients with mild or moderate OHSS can be on an outpatient 
basis. Oral simple analgesia and patient education are the principles of management in 
such cases. Patients are advised to avoid intercourse as it may increase the risk of 
ovarian torsion or bleeding. Nausea and vomiting can be treated with anti-emetics, 
such as cyclizine, metoclopramide or ondansentron. Patients with such symptoms can 
still be monitored on an outpatient basis, but may require more regular follow-up 
visits, which would include a clinical and ultrasound assessment to detect any 
potential increase in ascitic fluid and serial measurements of blood levels of 
haemoglobin, haematocrit, urea, creatinine and electrolytes. Close monitoring of the 
patient is important and includes at least daily assessment and clinical examination, to 
ensure that any progression to the severe form of the syndrome is promptly 
recognised. Patients are advised to maintain an adequate oral fluid intake of 2-3L/day 
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and to maintain light physical activity, which may decrease their risk of venous 
thromboembolism. 
 
Hospitalisation 
Hospitalisation is indicated in the case of severe OHSS. The Royal College of 
Obstetricians and Gynaecologists has advised that patients with symptoms and signs 
of severe or critical OHSS based on their classification, should be hospitalised. 
Similaly the American Society of Reproductive Medicine (ASRM) has set the 
following criteria for inpatient management of OHSS (Table 1.3).  
 
Clinical features Laboratory findings 
Severe abdominal pain haematocrit >45% 
Peritonism white blood cell count >15,000 
Inability to maintain oral intake  Na+ <135 mM 
Oliguria K+ >5.0 mM 
Tense ascites creatinine clearance <50 mL/min 
Dyspnoea serum creatinine >120 
Table 1.3. Hospital admission criteria for severe OHSS (ASRM Guideline on ovarian hyperstimulation 
syndrome) 
 
Prevention of ovarian hyperstimulation syndrome 
Many strategies have been employed to decrease the risk of OHSS in women 
undergoing IVF treatment. The use of lower gonadotrophin doses has been shown to 
reduce the incidence of OHSS in patients with polycystic ovarian syndrome (Marci et 
al, 2001). The introduction of GnRH antagonists has also significantly decreased the 
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incidence of OHSS in high-risk populations. Indeed the meta-analysis by Kolibianakis 
et al (2006) revealed a significant decrease in hospital admissions due to OHSS when 
a GnRH antagonist protocol was used instead of the prolonged administration of a 
GnRH agonist (OR: 0.46, 95% CI 0.26-0.82). 
 
The use of metformin in patients with polycystic ovarian syndrome has also been 
shown to reduce the incidence of OHSS in women with PCOS, without reducing 
pregnancy rates (Tso et al, 2009). Similarly dopamine agonists such as cabergoline 
have been shown to decrease the incidence of OHSS by binding to VEGFR-2 and 
hence decreasing vascular permeability (Soares et al, 2012). 
The use of hCG to trigger oocyte maturation is the major cause of OHSS since it 
causes excessive stimulation of the ovaries. As such, the development of alternative 
oocyte maturation triggers, which could result in physiological oocyte maturation 
without excessive stimulation has gained worldwide interest. To date, the only 
available alternative to hCG trigger during IVF treatment is the use of a single dose of 
a GnRH agonist, which leads to the endogenous release of LH. The release of VEGF 
is significantly reduced at the mRNA and the protein level, when a GnRH agonist is 
used instead of hCG (Cerillo et al, 2011). Consequently many trials have reported 
prevention of OHSS through the use of a GnRH agonist to induce oocyte maturation 
(Kol 2004, Engmann 2008, Griesinger 2008). However the use of a GnRH agonist 
trigger has been associated with a defective luteal phase and with consistently lower 
pregnancy rates compared to hCG (Griesinger et al, 2010). This is thought to be due 
to excessive stimulation of the GnRH receptor resulting in desensitisation and 
subsequent reduced secretion of LH during the luteal phase, which is required to 
maintain sex steroid production and endometrial receptivity in the luteal phase of the 
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cycle. As such there is a need to identify novel physiological triggers, which could 
result in physiological oocyte maturation without excessive stimulation during an IVF 
cycle. Kisspeptin is a recently identified hormone, which may have this potential. 
Kisspeptin is a recently identified hormone which stimulates endogenous GnRH 
release and subsequently gonadotrophins.  Hence kisspeptin may be able to 
effectively trigger oocyte maturation during an IVF cycle in a more physiological 
manner than currently used triggers for oocyte maturation. 
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Kisspeptin 
The KISS1 gene 
KISS1, which constitutes the gene that encodes kisspeptins, was first identified in 
1996 through its action as a metastasis suppressor gene in human malignant 
melanoma (Lee et al., 1996). Since it was first discovered in Hershey USA, it was 
named after the famous local chocolate product called ‘Kisses’. The SS in KiSS1 
stands for ‘suppressor sequence’. The KISS1 gene is located at chromosome 1q32 and 
consists of four exons with the first two not translated (West et al., 1998).  
The GPR54 receptor and its ligands 
G protein-coupled receptors form the largest category of human cell membrane 
receptors (Bockaert et al, 1999). Lee at al (1999) first described the novel GPR54 
receptor in the rat model. GPR54 is a G protein-coupled membrane receptor, which 
has a distinct distribution in human tissues. It is predominantly expressed in areas of 
the central nervous system (caudate nucleus, substantia nigra, hippocampus, 
amygdala and thalamus), endocrine organs (pituitary gland and pancreas) and the 
placenta. The highest expression of the GPR54 receptor has been identified in the 
pituitary and the placenta (Kotani et al). In fact, serum kisspeptin levels are 7000 
times higher compared to non-pregnant levels during the third trimester of pregnancy 
in humans (Horikoshi et al, 2003).  
 
The GPR54 gene is located at chromosome 19p13.3 and consists of five exons, which 
encode a protein of 398 amino acids and seven hydrophobic, transmembranic 
domains (Muir et al., 2001).  
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Upon binding to kisspeptin, the GPR54 receptor activates phospholipase C and 
subsequently recruits intracellular component messengers, such as inositol 
triphosphate and diacylglycerol. These intracellular mediators will in turn modify 
calcium release to mediate the function of kisspeptin (Muir et al., 2001; Liu et al., 
2008; Constantin et al., 2009). Activation of the GPR54 receptor will result in a 
biphasic rise of intracellular calcium, with an initial steep increase followed closely 
by a more sustained phase (Min et al., 2014).  
The kisspeptin receptor mediates the action of a family of ligand neuropeptides 
termed kisspeptins, which are encoded by the KISS-1 gene (Kotani et al, 2001). The 
KiSS-1 gene initially encodes a long 145- amino acid peptide, which is subsequently 
cleaved into a 54-amino acid product called kisspeptin-54. Kisspeptin-54 has been 
described as the endogenous ligand to the GPR-54 receptor (Ohtaky et al, 2001). 
Shorter peptidic fragments (14,13 and 10-amino acid long) have been identified as 
ligands to the GPR54 receptor, through a common C-terminal part, which is 
responsible for the high affinity binding and subsequent activation of the GPR54 
receptor (Kotani et al, 2001). 
 
At the level of the hypothalamus, specialised neurons release kisspeptin, which in turn 
stimulates the secretion of endogenous GnRH. GnRH stimulates the secretion of 
endogenous gonadotrophins (LH and FSH) from the pituitary gland (Irwig et al, 2004; 
Clarkson et al, 2006).  Seminara et al (2003) reported that mutations of the GPR54 
gene are the cause of autosomal recessive hypogonadotrophic hypogonadism in 
humans and as a result, the kisspeptin/GPR54 signaling is pivotal in the regulation 
and function of the hypothalamic-pituitary-gonadal axis.  
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Animal Studies 
Gottsch et al (2004) observed that KiSS-1 mRNA is predominantly expressed in the 
hypothalamic anteroventral periventricular (AVPV) nucleus and the preoptic 
periventricular (POPV) nucleus in mice. Furthermore, Messager et al (2005) were 
able to demonstrate that GPR54 transcripts are co-localised with GnRH neurons in the 
mouse hypothalamus. Clarkson et al (2006) used antisera against kisspeptin-10 and 
described three populations of kisspeptin neurons in the mouse model, located in the 
anteroventral periventricular nucleus (AVPV) and the preoptic periventricular nucleus 
(POPV) of the hypothalamus, the dorsomedial hypothalamus and the arcuate nucleus. 
Through dual immunofluorescence, they were able to demonstrate appositions 
between kisspeptin neuron fibres and GnRH neuron cell bodies. Interestingly they 
were also able to demonstrate a significant 10-fold sex difference (female-dominant) 
in the number of hypothalamic kisspeptin neurons. The same researchers (Clarkson et 
al, 2008) were subsequently able to demonstrate the absence of the LH surge in 
transgenic mice null for kisspeptin, or its receptor. 
 
Thompson et al (2004) were first able to demonstrate that exogenous administration 
of kisspeptin can potently stimulate the hypothalamic-pituitary-gonadal axis in the rat 
model. Through intra-cerebroventricular and intravenous administration of kisspeptin-
10 to adult male rats, they described a dose-dependent increase in plasma LH, FSH 
and testosterone at 20 and 60 minutes following kisspeptin injection. In addition, 
intravenous infusion of kisspeptin in ovariectomised sheep produced an increase of 
serum FSH and LH release (Caraty at al. 2007). 
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To further study the roles of GPR54 signalling in primates, Shahab et al (2005) 
implanted castrated juvenile male monkeys with a cerebroventricular cannula and a 
central venous catheter. Both intracerebroventricular and intravenous administration 
of kisspeptin-10 induced a prominent secretion of LH within 30 minutes from 
injection. 
Inoue et al (2011) were able to abolish the proestrus LH surge in shrews by a specific 
monoclonal antibody, which blocks the actions of hypothalamic kisspeptin. 
Conversely, Matsui et al (2004) demonstrated that the peripheral administration of 
kisspeptin promotes oocyte maturation in adult female rats primed with 
gonadotrophins. 
 
Kisspeptin neurons show sexual dimorphism 
Current evidence has identified the presence of sexual dimorphism in kisspeptin 
pathways in humans. The female hypothalamus exhibits significantly more kisspeptin 
fibres compared to those seen in men (Hrabovszky et al., 2010). A similar sex 
difference exists for the expression of kisspeptin cell bodies, which are observed only 
in the female periventricular zone (Hrabovszky et al., 2010). Similarly fewer 
kisspeptin cell bodies are present in the male infundibulum, when compared to the 
high number of kisspeptin cell bodies in the female (Hrabovszky et al., 2010). Similar 
sex differences can be seen in the arcuate nucleus of sheep (Cheng et al., 2010). 
Importantly pre-ovulatory positive feedback by sex steroids appears to be unique to 
females. The adult female rat hypothalamus contains 10-fold kisspeptin neurons 
compared to males in the rostral periventricular region of the third ventricle (RP3V) 
region. Conversely, the arcuate nucleus regulating negative sex steroid feedback does 
 
 
 
 
 
45 
not display such sexual dimorphism (Clarkson and Herbison, 2006; Kauffman et al., 
2007). 
 
Kisspeptin and metabolism 
Reproductive function in humans may be influenced by extremes of nutrition, 
whether this refers to under-nutrition or obesity. Kisspeptin could be the link between 
nutritional status and reproductive function by translating information from energy 
stores into regulation of pulsatile GnRH secretion. When pubertal rats and monkeys 
were subject to fasting, the subsequent expression of Kiss1 mRNA and gonadotrophin 
secretion were reduced (Castellano et al., 2005; Cota et al., 2006; Roa et al., 2009; 
Wahab et al., 2011). Kisspeptin has been shown to restore delayed vaginal opening 
and to increase gonadotrophin and sex steroid levels associated with prolonged under-
nutrition in rats of pre-pubertal age (Navarro et al., 2004, Castellano et al., 2005). 
Humans with leptin / leptin receptor mutations can develop hypogonadism (Farooqi 
and O'Rahilly, 2009). Although the leptin receptor is not expressed on GnRH 
neurons, 40% of arcuate nucleus kisspeptin neurons in mice express the leptin 
receptor (Smith et al., 2006). This finding suggests the presence of a potential role of 
kisspeptin in mediating leptin signals on the HPG axis. Leptin-deficient mice 
demonstrate a decrease in the expression of Kiss1 mRNA, which may be partially up-
regulated by leptin (Smith et al., 2006). However mice with a selective deletion of the 
leptin receptor from kisspeptin neurons exhibit a normal pubertal development, and 
fertility, which demonstrates that the action of leptin on kisspeptin neurons is not 
mandatory for these reproductive processes to occur (Donato et al., 2011). 
Decreased testosterone levels have been observed in obese and type 2 diabetic men. A 
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decrease in GnRH secretion has been implicated as the aetiology (Dandona et al., 
2008). Streptozocin treated rats, which have been rendered diabetic, showed 
decreased levels of hypothalamic Kiss1 mRNA with resulting low circulating 
gonadotrophins and sex steroids (Castellano et al., 2006, 2009). This might suggest 
that decreased secretion of kisspeptin could be the potential, pathophysiological 
mechanism underlying hypogonadotropic hypogonadism in obese and diabetic 
patients (George et al., 2010). Indeed George et al (2013) demonstrated that 
kisspeptin-10 could increase the frequency of LH pulse secretion in hypogonadal, 
type 2 diabetic men (George et al., 2013). Possible mechanisms for this down-
regulation of kisspeptin pathways include increased oestrogen negative feedback, 
which appears to be significantly elevated in obesity (Schneider et al., 1979). Other 
candidate mechanisms include resistance to leptin (Finn et al., 1998), hyperglycaemia 
and insulin resistance (Castellano et al., 2006, 2009). 
In conclusion the available data suggest that kisspeptin can convey information from 
energy stores to GnRH neuron and regulate reproductive function accordingly. This 
important finding highlights a potential therapeutic role of kisspeptin to restore the 
reproductive function in conditions such as anorexia nervosa and diabetes. 
 
Human studies 
Dhillo et al (2005) performed a double-blind, placebo-controlled, crossover study and 
administered an intravenous infusion of kisspeptin-54 and a control intravenous 
infusion of normal saline 0.9% three days apart in random order to 6 healthy, adult 
male volunteers. They used a dose of 4pmol/kg.min for the initial 30 minutes and 
halved the dose for the remaining 60 minutes of the infusion. The infusion of 
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kisspeptin-54 was associated with a significant increase in serum levels of LH and 
testosterone compared with saline infusion (Figure 2.1). 
 
 
Figure 2.1. Mean plasma kisspeptin-IR, LH, FSH, inhibin B and testosterone after kisspeptin-54 and 
control saline infusions. (Dhillo et al, 2005) 
 
 
The subjects included in the study were assessed for any blood pressure or pulse 
changes every 15 minutes for the first 3 hours and every 30 minutes thereafter. No 
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changes in blood pressure or pulse were recorded. The patients reported no nausea or 
other adverse symptoms during or after the kisspeptin administration. 
 
Chan et al (2011) confirmed the findings of Dhillo et al (2005). They administered a 
single intravenous bolus injection of kisspeptin-10 to thirteen healthy male volunteers 
and reported that kisspeptin-10 resulted in a single, large LH pulse in the patients 
included.  
 
Dhillo et al (2007) subsequently investigated the effects of kisspeptin-54 on LH 
secretion during the different phases of the menstrual cycle in healthy female 
volunteers in a double-blind, placebo-controlled study (Dhillo et al, 2007). Each 
volunteer received a subcutaneous bolus dose of kisspeptin (0.4nmol/kg) on one day 
and then a bolus subcutaneous injection of saline on the other day. These injections 
were performed during the follicular, the pre-ovulatory and the luteal phase of the 
menstrual cycle and alternated between kisspeptin and placebo over the course of two 
menstrual cycles. The study days of the different menstrual cycle phases were 
separated by a minimum period of seven days. This dose of kisspeptin-54 was 
associated with a significant rise in plasma LH and FSH in all three phases of the 
menstrual cycle (Figures 2.2 & 2.3). 
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Figure 2.2. Mean ± SEM increase in plasma LH after saline or kisspeptin injection in the various 
phases of the female menstrual cycle. (A:follicular, B:pre-ovulatory, C:luteal, D: all three phases). ***, 
P<0.001. (Dhillo et al, 2007) 
 
 
 
Figure 2.3. Mean ± SEM increase in plasma FSH after saline or kisspeptin injection in the various 
phases of the female menstrual cycle (A:follicular, B:pre-ovulatory, C:luteal, D: all three phases). ***, 
P<0.001. (Dhillo et al, 2007) 
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When the effects of kisspeptin administration were compared for the different phases 
of the menstrual cycle, a significantly greater increment in plasma LH and FSH was 
observed in the pre-ovulatory phase of the cycle compared to the follicular and luteal 
phase (Figure 2.4). 
 
Figure 2.4. Change in plasma LH (iu/l) (Y-axis) after a sc bolus injection of (0.4 nmol/kg) kisspeptin-
54 (KP) or saline injection in the different phases of the menstrual cycle. ***, P<0.001 (Dhillo et al, 
2007) 
Jayasena et al (2009) performed a prospective, randomised, double-blinded study to 
investigate the effect of kisspeptin-54 in women with hypothalamic amenorrhoea. Ten 
patients with hypothalamic amenorrhoea were administered subcutaneous injections 
of kispeptin-54 at a dose of 6.4nmol/kg twice a day for a period of two weeks. The 
response to kisspeptin-54 injections was investigated by assessing the serum 
gonadotrophin and oestradiol levels on the 1st and 14th day (4 hours post injection). 
The results indicated a potent increase in serum LH and FSH on the first day of 
injections. This response appeared to be significantly reduced by day 14, suggesting 
that chronic administration of kisspeptin may result in desensitisation of its effects on 
FSH and LH release (Figure 2.5). 
Chan et al (2012) administered an intravenous bolus dose of kisspeptin-10 to ten 
women in the early follicular phase, three in the preovulatory phase and fourteen in 
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the midluteal phase. They demonstrated a varied gonadotrophin secretory response, 
which depended on the phase of the menstrual cycle. They also reported that the 
response to kisspeptin-10 (based on the GnRH-induced LH surge) was particularly 
prominent in the preovulatory phase of the menstrual cycle. 
 
Based on this evidence, it is possible that kisspeptin could potentially lead to a more 
physiological release of an endogenous LH surge during a cycle of controlled ovarian 
stimulation and IVF. In addition, whilst hCG only acts through an LH-like 
mechanism, kisspeptin has been demonstrated to induce the concomitant release of 
FSH. 
 
 
Figure 2.5. Effects of kisspeptin-54 and saline injection on the first day (A,B,C) and the 14th day 
(D,E,F) to plasma levels of LH, FSH and serum oestradiol. Data are shown at mean ± SEM. *,P<0.05. 
***, P<0.001 (Jayasena et al, 2009) 
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Although the mid-cycle surge of LH has been primarily associated with final oocyte 
maturation and ovulation, FSH has been shown to increase the formation of LH 
receptors in granulose cells and promote nuclear maturation and cumulus expansion 
(Eppig et al, 1979; Yding Andersen et al, 1999). As such kisspeptin may be more 
beneficial than hCG for triggering oocyte maturation, as it may result in a more 
physiological LH surge, because it stimulates the release of endogenous GnRH, which 
should also result in a reduced risk of OHSS in women undergoing IVF treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
53 
 
 
CHAPTER 3 
Kisspeptin as potential novel trigger of  
 oocyte maturation during IVF 
treatment 
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Hypothesis 
Kisspeptin is a novel physiological trigger for oocyte maturation in IVF treatment. 
 
Aim  
The aim of the study was to assess whether the administration of kisspeptin can 
induce oocyte maturation in women undergoing an IVF cycle. This is the first human 
study that investigates the use of kisspeptin in an assisted conception cycle. 
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Methods 
Regulatory approval 
This study was approved by the Hammersmith and Queen Charlotte’s Research Ethics 
Committee, London (reference: 10/H0707/2). The study was performed in the IVF 
Unit at Hammersmith Hospital under a license from the UK Human Fertilisation and 
Embryology Authority (HFEA). Written informed consent was obtained from all 
subjects. Approval of this study as a Clinical Trial of an Investigative Medicinal 
Product was granted by the Medicines and Healthcare Products Regulatory Agency, 
UK. The study was registered on the National Institutes of Health Clinical Trials 
database (NCT01667406). The study was performed in accordance with the 
Declaration of Helsinki.  
 
Peptide 
Kisspeptin-54 was synthesised, purified and tested to Good Manufacturing Practice 
standards by Bachem (Bachem Holding AG, Bubendorf. Switzerland). Vials of 
freeze-dried kisspeptin-54 were stored at -20OC and reconstituted in 0.5ml of 0.9% 
saline as described previously (Dhillo et al, 2005). 
 
Subjects 
Sixty infertile patients with an indication for in vitro fertilisation treatment were 
screened for participation at Hammersmith Hospital between August 2012 and 
September 2013. Eligible patients received one IVF treatment cycle; all treatment 
costs for this single IVF cycle were covered by study participation since the efficacy 
of kisspeptin to induce oocyte maturation was unknown prior to commencing the 
study. The inclusion criteria were: age 18-34years; early follicular phase serum FSH 
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≤12mIU/mL; serum anti-Müllerian hormone (AMH) 10-40pmol/L; intact ovaries 
bilaterally; regular, menstrual cycles (24-35 days long); body mass index (BMI) of 
18-29kg/m2. Exclusion criteria were: moderate/severe endometriosis (as diagnosed 
during previous laparoscopy); previous poor response or more than one previous 
cycle of IVF treatment; evidence of clinical and/or biochemical hyperandrogenaemia 
or the presence of polycystic ovarian syndrome.  
 
Study outcomes 
The primary outcome of the study was oocyte maturation during a single IVF 
treatment cycle. Oocyte maturation was assessed in two different ways: the absolute 
number of mature oocytes and the proportion of collected oocytes that were mature. 
The oocytes were classed as mature by identifying the first polar body and by the 
round appearance of the ooplasm (Macklon et al, 2006). 
 
The secondary outcomes of the study were the serum levels of reproductive hormones 
following the administration of kisspeptin-54, fertilisation rate, embryo quality, the 
rate of biochemical pregnancy at 12 days following embryo transfer, and the clinical 
pregnancy rate at 6 weeks’ gestation. Fertilisation rate refers to the number of two 
pronuclear zygotes divided by the total number of mature oocytes injected (Macklon 
et al, 2006). Biochemical pregnancy was defined as a plasma hCG level >10mIU/mL 
12 days after the embryo transfer procedure. Clinical pregnancy was defined as the 
presence of an intrauterine gestational sac with an active fetal heartbeat at 6 weeks’ 
gestation. The outcomes of pregnancy and live birth rates were documented in all 
women with a diagnosed clinical pregnancy. 
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Dose allocation 
The efficacy of kisspeptin to induce oocyte maturation prior to commencing the study 
was not known, because kisspeptin had not previously been administered to infertile 
patients undergoing IVF treatment. This obviously posed ethical implications for the 
present study. Consequently the dose allocation was designed to minimise the number 
of patients exposed to kisspeptin doses which would not result in clinically effective 
oocyte maturation. As such a modification of the conventional 3+3 trial design was 
employed. The first nine patients would be equally randomised between the three 
lowest kisspeptin doses of 0.4, 0.8 and 1.6nmol/kg. If fewer than 2 women in each 
group demonstrated proven oocyte maturation, then the following nine women would 
be randomised between the three higher kisspeptin doses of 3.2, 6.4 and 12.8nmol/kg. 
The clinical ease of oocyte retrieval after kisspeptin-54 administration (compared 
with the trigger most commonly used in the clinical setting – hCG) was also 
documented. The reason behind this approach was that a clinically effective 
kisspeptin dose should result in mature oocytes that could be retrieved with 
comparable clinical ease to that associated with the currently available and widely 
used oocyte maturation triggers (i.e hCG). As a result the clinical ease of collection 
was graded from 1 to 4 by experienced IVF clinicians clinicians, who were blinded to 
the kisspeptin dose allocation. The grading system is as follows:  
• 1, not feasible to collect any oocytes;  
• 2, significantly more difficult than what expected during a routine IVF cycle 
using hCG for oocyte maturation (excessive number of  follicular flushing 
attempts were needed in order to aspirate oocytes and scanty number of 
granulosa cells present in the obtained aspirates);  
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• 3, slightly more difficult compared to using hCG as maturation trigger 
(present but less abundant granulosa cells in the follicular aspirates. Cumulus 
cells appeared more densely packed than following hCG triggering);  
• 4, comparable level of clinical ease of oocyte retrieval when compared with 
hCG.  
 
When a kisspeptin dose was shown to induce proven oocyte maturation in at least 2 
patients in a cohort of 3, then additional patients would be recruited to increase the 
sample size of that dose group to a minimum of 15. An independent Data Monitoring 
and Ethics Committee approved the dose allocation. Clinicians, who were blinded to 
the dose allocation of patients, performed all transvaginal oocyte retrievals. The 
embryologists and the included patients were also blinded to the kisspeptin dose 
allocation. During each phase of the study, simple randomisation was used to allocate 
patients to kisspeptin doses.  
 
Sample size 
When oocyte maturation in patients undergoing IVF is the primary endpoint, there is 
no relevant data on the use of kisspeptin-54 as an oocyte maturation trigger and 
therefore no data was available on which sample sizes estimates could be based upon 
prior to commencing this study. However, current evidence (Dubuisson et al, 1991) 
suggested an association between successful egg maturation and elevation of LH; 
successful egg maturation did occur after a mean serum LH rise to 106 IU/L 4hours 
after a GnRH agonist trigger in a standard GnRH antagonist ovarian stimulation 
protocol. In addition we have previously noted that kisspeptin-54 at a dose of 
12.8nmol/kg can increase serum LH up to 148 IU/L in healthy females during the 
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preovulatory phase of their cycle. Using the 2-group t-test approach, it was estimated 
that a sample size of 13 patients per effective kisspeptin dose would have a 90% 
power to detect a difference of 148 IU/L between any two groups (two-sided 5% 
significance level without correction for multiplicity and common standard deviation 
of 78 IU/L). We anticipated that the drop-out rate in our sample would be less than 
10%, based on similar studies performed in the past, as infertile patients undergoing 
IVF are highly motivated. As a result a minimal size of 15 women at each clinically 
effective kisspeptin dose was calculated. The recruitment process ceased once this 
sample size target had been achieved for the clinically effective kisspeptin doses of 
6.4 and 12.8 nmol/kg. For ethical reasons, however, patients who had already been 
screened and consented at the time of stopping recruitment were allowed complete the 
study protocol; this resulted in a total recruitment of 24 patients for each of the 
effective kisspeptin doses of 6.4 and 12.8 nmol/kg. 
 
Protocol 
All of the recruited patients underwent controlled ovarian stimulation using a 
recombinant FSH and GnRH antagonist protocol. A single dose of kisspeptin-54 was 
used as the oocyte maturation trigger. 
 
Superovulation protocol 
Once daily subcutaneous recombinant FSH injections (Gonal F 150IU, Merck Serono, 
Geneva, Switzerland, administered at 9am daily) were commenced on day 2 of the 
menstrual cycle. A pelvic ultrasound was performed five days later to assess the 
individual progress of ovarian follicular development. Daily subcutaneous injections 
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of a GnRH antagonist (Cetrotide 0.25mg, Merck Serono, injected at 9pm daily) were 
employed to prevent a premature LH surge. The GnRH antagonist was commenced 
once the lead follicle had reached a mean diameter >14mm. Additional ultrasound 
examinations were performed on an individual patient basis according to size of the 
growing follicles and the response to superovulation (Figure 3.1). 
                         Oocyte retrieval 36 hours later 
 
 
 
 
Day   1   2  3 4 5 6 7 8 9 10 11  12 
 
 
 
                        Kisspeptin SC when 3 follicles ≥ 18mm 
 
Figure 3.1. The stimulation protocol used in the study. Once daily subcutaneous recombinant FSH 
injections commenced on day 2 of the menstrual cycle. The GnRH antagonist commenced once the 
lead follicle had reached a mean diameter >14mm. When at least three ovarian follicles ≥18mm 
diameter were visible on ultrasound, a subcutaneous bolus injection dose of kisspeptin-54 was 
administered between 2030 and 2130h. The transvaginal oocyte retrieval was performed 36 hours later. 
 
 
Kisspeptin-54 trigger of egg maturation 
When at least three ovarian follicles ≥18mm diameter were visible on ultrasound, a 
subcutaneous bolus injection dose of kisspeptin-54 was administered by an 
investigator to trigger egg maturation. Kisspeptin-54 was administered 36h prior to 
egg retrieval (between 2030 and 2130h). Injections of FSH were stopped 12h prior to 
kisspeptin-54. In order to minimise any effect that the GnRH antagonist had on 
kisspeptin-54 response the last injection of GnRH antagonist was administered 24 
Recombinant FSH (150iu Gonal-f) daily 
GnRH antagonist when follicle >14mm 
 
 
 
 
 
61 
hours prior to kisspeptin-54 (Damewood et al, 1989; Golan et al, 1989). Serum LH, 
FSH, oestradiol and progesterone were measured immediately before and 12h after 
kisspeptin-54 injection, and at the time of egg retrieval in all women. 
 
 
The transvaginal oocyte retrieval was performed under ultrasound guidance 36 hours 
after the bolus injection of kisspeptin-54. The procedure was performed under 
intravenous sedation using propofol given by an anaesthetist and the collected mature 
oocytes were fertilised by intracytoplasmic sperm injection utilising produced sperm 
from the male partner.  
 
Reproductive hormone secretion during the 12h following kisspeptin injection  
A subgroup of women receiving the two highest doses of kisspeptin-54 (6.4 or 
12.8nmol/kg, n=10/dose) underwent overnight measurements of serum LH, FSH, 
oestradiol and progesterone, and plasma kisspeptin immunoreactivity just prior to and 
during the 12 hours following kisspeptin-54 injection (t=-30, -15, 0, 30, 60, 90, 120, 
150, 180, 240, 360, 480, 600 and 705minutes post-injection). These hormonal 
measurements allowed us to determine a detailed time course of reproductive 
hormone release following kisspeptin-54 injection. 
 
Egg retrieval, fertilisation, and re-implantation of embryos 
Transvaginal, ultrasound-directed oocyte retrieval was carried out 36h following 
kisspeptin-54 injection, and intracytoplasmic sperm injection was performed in all 
study cycles. One or two embryos of highest quality during morphological assessment 
were transferred to the uterine cavity 3-5 days following egg collection. Progesterone 
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(400mg twice daily suppository/pessary) (Cyclogest; Actavis UK Limited, UK) and 
oestradiol valerate (2mg orally three times daily) (Progynova; Bayer Plc, UK)  were 
started after egg collection and continued until 12 weeks gestation for luteal phase 
supplementation.  
 
Hormonal assay methodology 
Blood samples were collected as previously described (Caraty et al, 2007; Dhillo et al, 
2005; Jayasena et al, 2009). Serum LH, FSH, oestradiol, and progesterone were 
measured using automated chemiluminescent immunoassays (Abbott Diagnostics, 
Maidenhead, UK). Interassay coefficients of variation were as follows: LH, 3.4%; 
FSH, 3.5%; oestradiol, 3.4%; progesterone, 1.8%.  Limits of detectability for each 
assay were as follows: LH 0.07mIU/ml; FSH 0.05mIU/ml; oestradiol 70pmol/l 
(19pg/mL); progesterone 0.3nmol/L (0.1ng/mL).  
AMH was measured using an enzyme linked immunosorbent assay (Beckman Coulter 
Inc, Brea, CA, USA). The reference range was 2.2-48.5pmol/L (0.3-6.8ng/mL). The 
lower limit of detection was 0.6pmol/l (0.08ng/mL). The interassay coefficient of 
variation was 4.6%; the intra-assay coefficient of variation was 4.0%. 
Measurement of plasma kisspeptin immunoreactivity (IR) was performed using an 
established RIA (Caraty et al, 2007; Dhillo et al, 2005; Jayasena et al, 2009). The 
antibody cross-reacted 100% with human kisspeptin-54, kisspeptin-14, and 
kisspeptin-10 and less than 0.01% with other related arginine-phenylalanine amide 
proteins, including prolactin-releasing peptide, arginine-phenylalanine amide-related 
peptide 1, arginine-phenylalanine amide-related peptide 2, arginine-phenylalanine 
amide-related peptide 3, QRFP43, neuropeptide FF, and neuropeptide AF. The limit 
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of detectability was 2pmol/l, and the intra- and interassay coefficients of variation 
were 8.3 and 10.2%, respectively.  
 
Results 
Kisspeptin dose allocation and baseline characteristics.The first two patients were 
randomised to a kisspeptin-54 dose of 1.6 nmol/kg; the oocyte retrieval was 
significantly more difficult when compared with a typical, routine, transvaginal 
oocyte retrieval using human chorionic gonadotropin (hCG) as the oocyte maturation 
trigger (Figure 3.2). Consequently we decided to proceed to the doses of 3.2, 6.4, and 
12.8 nmol/kg. A clinically difficult oocyte retrieval was reported for all 3 patients 
who received the 3.2nmol/kg kisspeptin-54 dose. Consequently the next patients were 
randomized 1:1 between 6.4 and 12.8 nmol/kg kisspeptin (n = 24 per group). Two 
independent clinical trialists approved the dose allocation. No significant differences 
in baseline characteristics were identified between the dose groups (Table 3.1). 
 
Figure 3.2. Enrolment of patients, who were administered kisspeptin-54 as oocyte maturation trigger in 
their IVF/ICSI cycle 
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Kisspeptin-54 dose (nmol/kg) 
 1.6 3.2 6.4 12.8 
N 2 3 24 24 
Age(yr) 30 (28,32) 31 (31,32) 32 (29,34) 30 (29,33) 
Weight (kg) 66 (65,67) 59 (58,61) 62 (55,67) 64 (59,69) 
Body mass index 
(kg/m2) 
23 (22,23) 22 (22,23) 22 (21,24) 23 (23,25) 
Antral Follicle 
Count 
30 (28,31) 24 (20,28) 20 (16,26) 20 (17,26) 
AMH 21 (18,23) 13 (12,19) 18 (14,26) 21 (12,25) 
Cause of 
infertility 
 
Male 1 (50%) 0 (0%) 9 (38%) 7 (29%) 
Tubal 0 (0%) 0 (0%) 5 (21%) 5 (21%) 
Other 0 (0%) 1 (33%) 2 (8%) 5 (21%) 
Unknown 1 (50%) 2 (67%) 8 (33%) 7 (29%) 
Number of 
follicles 
16 (16,16) 20 (18,30) 20 (16,24) 19 (15,24) 
Follicles >14mm 8 (8,9) 11 (11,14) 11 (8,12) 9 (8,12) 
Table 3.1. Baseline characteristics of patients administered kisspeptin-54. Continuous variables are 
presented as medians (lower, upper quartile) and categorical variables are presented as totals 
(percentages). Other known causes of infertility include endometriosis or ovarian endometriomas. The 
number of follicles was calculated during the last ultrasound assessment prior to the kisspeptin-54 
trigger. 
 
Ease of oocyte collection 
The oocyte retrievals were carried out in line with the routine departmental policy 
regarding oocyte retrieval in our IVF unit using other established triggers of oocyte 
maturation. The embryologist routinely informs the clinician of the presence of an 
oocyte or granulosa cells in the follicular aspirate before the clinician progresses to 
the next follicle.  Eggs were collected using a single-lumen, 16-gauge ovum 
aspiration needle (Cook Medical, Bloomington, USA) for the majority of patients. If 
there were less than five follicles with a diameter greater than 14mm on the day of the 
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kisspeptin trigger, or when no oocyte was retrieved after aspiration of the first three 
follicles, a double-lumen 16-gauge ovum aspiration needle (Cook Medical, 
Bloomington, USA), which allows for follicular flushing with Hartmann’s solution 
was employed. We graded the clinical ease of the oocyte retrieval procedure in 
comparison to what a clinician would expect in a routine, transvaginal oocyte retrieval 
after the administration of hCG as the oocyte maturation trigger in a normoresponsive 
patient. The results for the patients of the study are presented below (Table 3.2). 
Clinical ease of 
collection 
1.6 nmol/kg 
 N            % 
3.2 nmol/kg 
 N            % 
6.4 nmol/kg 
 N            % 
12.8 nmol/kg 
 N            % 
1 0 0% 0 0% 2 8% 1 4% 
2 2 100% 3 100% 5 21% 3 12% 
3 0 0% 0 0% 3 12% 2 8% 
4 0 0% 0 0% 14 58% 18 75% 
Total 2 3 24 24 
Table 3.2. The clinical ease of oocyte retrieval was arbitrarily graded as follows (doses of kisspeptin-
54 are in nmol/kg). 1:No eggs collected, 2: Substantially more difficult compared to an oocyte retrieval 
using hCG, 3: Slightly more difficult compared to an oocyte retrieval using hCG, 4: Comparable 
compared to an oocyte retrieval using hCG. Percentages in right hand column signify the proportion of 
patients randomised to each dose with that clinical ease of collection score. 
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Primary outcome 
The use of kisspeptin to induce egg maturation. 
The study was designed to assess if oocyte maturation can be achieved in women 
having IVF treatment following kisspeptin-54 administration. Oocyte maturation was 
observed with all administered doses of kisspeptin-54 (Table 3.3, Figure 3.3). Similar 
rates of oocyte maturation (percentage of recovered oocytes that were mature), 
between 75% and 85%, were observed following all administered kisspeptin-54 
doses. However, oocyte yield (the proportion of oocytes recovered when compared 
with the expected number, i.e., number of follicles > 14 mm diameter) and the 
absolute number of mature eggs appeared to increase with increasing doses of 
kisspeptin. 
Kisspeptin-54 
dose (nmol/kg) 1.6 (n=2) 3.2 (n=2) 6.4 (n=24) 12.8 (n=24) 
M2 4.5     (3.5) 4.3    (1.5) 7.5   (3.8) 8.8   (4.0) 
%M2 75      (35) 79     (36) 79     (22) 85     (16) 
Oocyte yield 49      (29) 36     (18) 76     (49) 103   (53) 
Table 3.3. Summary of oocyte maturation after the use of kisspeptin-54 as oocyte maturation trigger. 
M2 refers to the absolute number of mature oocytes collected. %M2 refers to the percentage of 
collected oocytes that were mature. Oocyte yield refers to the percentage of mature oocytes collected 
from the number of follicles >14mm in mean diameter at the last ultrasound assessment prior to 
kisspeptin administration. Results are presented as mean (SD). 
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Figure 3.3. Mature eggs per patient and mature eggs per eggs collected (%) for the different kisspeptin 
dose groups. 
Secondary outcomes 
Circulating levels of hormones following kisspeptin-54 administration.  
Circulating levels of reproductive hormones were measured just before, 12 and 36 
hours following kisspeptin-54 injection in all patients (except for a single patient who 
missed the 12-hour blood test). Serum LH, FSH, and progesterone levels appeared to 
be elevated 12 hours after the administration of kisspeptin-54 (Tables 3.4; 3.5; 3.6; 
3.7). 
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 N Mean SD Range Median Lq,Uq Gm 
LH (mIU/ml)  
0 hours 2 0.8 0.1 0.7,0.8 0.8 0.7,0.8 0.7 
12 hours 2 6.6 4.7 3.3,9.9 6.6 4.9,8.2 5.7 
36 hours 2 2.2 0.2 2.1,2.4 2.2 2.2,2.3 2.2 
FSH (mIU/ml)  
0 hours 2 6.2 1.8 4.9,7.4 6.2 5.5,6.8 6.0 
12 hours 2 6.9 0.7 6.4,7.4 6.9 6.7,7.2 6.9 
36 hours 2 4.9 0.7 4.4,5.4 4.9 4.7,5.2 4.9 
OeEstradiol 
(x103 pmol/l) 
 
0 hours 2 4.0 1.7 2.8,5.2 4.0 3.4,4.6 3.8 
12 hours 2 5.9 0.8 5.3,6.5 5.9 5.6,6.2 5.9 
36 hours 2 2.2 0.1 2.1,2.2 2.2 2.2,2.2 2.2 
Progesterone 
(nmol/l) 
 
0 hours 2 1.0 0.0 1.0,1.0 1.0 1.0,1.0 1.0 
12 hours 2 7.5 0.7 7.0,8.0 7.5 7.2,7.8 7.5 
36 hours 2 5.5 2.1 4.0,7.0 5.5 4.8,6.2 5.3 
 
Table 3.4. Circulating levels of gonadotrophins, oestradiol and progesterone following administration of 1.6 
nmol/kg kisspeptin-54 (n=2) as oocyte maturation trigger. Serum LH (mIU/ml), FSH (mIU/ml), oestradiol 
(x103 pmol/l) and progesterone  (nmol/l) were measured at 0 hours (just before injection), 12 hours after 
injection and 36 hous after injection (at the time of the oocyte retrieval).  
Lq: lower quartile, Uq: upper quartile, Gm: geometric mean 
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Table 3.5. Circulating levels of gonadotrophins, oestradiol and progesterone following administration of 3.2 
nmol/kg (n=3) kisspeptin-54 as oocyte maturation trigger. Serum LH, FSH, oestradiol and progesterone 
were measured at 0 hours (just before injection), 12 hours after injection and 36 hours after injection (at the 
time of the oocyte retrieval). 
   Lq: lower quartile, Uq: upper quartile, Gm: geometric mean 
 
 N Mean SD Range Median Lq,Uq Gm 
LH (mIU/ml)  
0 hours 3 1.4 1.3 0.4,2.9 0.8 0.6,1.8 1.0 
12 hours 2 3.8 3.3 1.5,6.2 3.8 2.7,5.0 3.0 
36 hours 3 1.1 0.6 0.4,1.5 1.3 0.8,1.4 0.9 
FSH (mIU/ml)  
0 hours 3 8.3 3.4 6.1,12.2 6.7 6.4,9.4 7.9 
12 hours 2 9.7 3.3 7.3,12.0 9.7 8.5,10.8 9.4 
36 hours 3 5.2 1.4 3.7 6.5 5.3,5.9 5.0 
Oestradiol 
(x103 pmol/l) 
 
0 hours 3 13.3 2.9 10.5,16.2 13.2 11.8,14.7 13.1 
12 hours 2 16.6 2.0 15.2,18.0 16.6 15.9,17.3 16.5 
36 hours 3 7.4 1.5 5.9,8.9 7.4 6.7,8.1 7.3 
Progesterone 
(nmol/l) 
 
0 hours 3 3.7 3.1 1.0,7.0 3.0 2.0,5.0 2.8 
12 hours 2 22.0 5.7 18.0,26.0 22.0 20.0,24.0 21.6 
36 hours 3 8.0 2.0 6.0,10.0 8.0 7.0,9.0 7.8 
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Table 3.6. Circulating levels of gonadotrophins, oestradiol and progesterone following  administration of 
6.4 nmol/kg (n=24) kisspeptin-54 as oocyte maturation trigger. Serum LH, FSH, oestradiol and 
progesterone were measured at 0 hours (just before injection), 12 hours after injection and 36 hours after 
injection (at the time of the oocyte retrieval). 
Lq: lower quartile, Uq: upper quartile, Gm: geometric mean 
 
 
 N Mean SD Range Median Lq,Uq Gm 
LH (mIU/ml)  
0 hours 24 1.3 1.1 0.4,4.2 0.8 0.4,1.8 0.9 
12 hours 24 7.9 8.0 0.7,39.2 5.5 2.8,11.2 5.4 
36 hours 24 1.4 2.1 0.4,10.6 0.7 0.6,1.2 5.4 
FSH (mIU/ml)  
0 hours 24 9.1 2.6 5.2,16.0 7.7 7.3,10.5 8.8 
12 hours 24 10.3 2.3 6.1,14.8 10.2 8.5,12.3 10.1 
36 hours 24 6.2 1.4 4.1,9.7 6.3 5.3,6.8 6.1 
Oestradiol 
(x103 pmol/l) 
 
0 hours 23 7.5 3.8 1.1,16.6 6.7 5.8,9.1 6.4 
12 hours 24 8.9 3.3 2.6,16.4 9.3 6.8,10.3 8.3 
36 hours 24 4.1 2.5 1.3,12.0 3.2 2.8,4.4 3.5 
Progesterone 
(nmol/l) 
 
0 hours 24 2.7 1.9 0.5,9.0 2.0 1.0,3.2 2.1 
12 hours 24 16.8 8.5 3.0,33.0 17.0 9.8,20.5 14.5 
36 hours 24 10.2 5.9 2.0,21.0 9.0 5.8,14.2 8.3 
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Table 3.7. Circulating levels of gonadotrophins, oestradiol and progesterone following administration of 
12.8 nmol/kg (n=24) kisspeptin-54 as oocyte maturation trigger. Serum LH, FSH, oestradiol and 
progesterone were measured at 0 hours (just before injection), 12 hours after injection and 36 hours after 
injection (at the time of the oocyte retrieval). 
Lq: lower quartile, Uq: upper quartile, Gm: geometric mean 
 
 
 
 N Mean SD Range Median Lq,Uq Gm 
LH (mIU/ml)  
0 hours 24 1.3 1.4 0.4,5.7 1.0 0.5,1.4 1.0 
12 hours 24 8.8 5.3 1.0,25.4 8.0 5.0,12.3 7.3 
36 hours 24 1.2 0.9 0.4,3.9 0.9 0.6,1.4 0.9 
FSH (mIU/ml)  
0 hours 24 8.6 2.2 5.0,13.2 8.9 6.8,10.1 8.3 
12 hours 24 10.8 2.5 6.1,17.9 10.3 9.1,12.7 10.6 
36 hours 24 6.1 1.3 3.8,8.6 6.0 5.2,6.9 5.9 
Oestradiol 
(x103 pmol/l) 
 
0 hours 24 7.5 3.8 2.2,17.5 7.3 5.3,9.5 6.6 
12 hours 24 8.4 3.7 2.1,15.8 7.6 5.9,11.2 7.5 
36 hours 24 3.6 2.6 1.0,13.1 3.0 2.2,4.3 2.9 
Progesterone 
(nmol/l) 
 
0 hours 24 3.5 2.9 1.0,15.0 3.0 2.0,4.2 2.7 
12 hours 24 20.2 10.1 8.0,45.0 15.8 12.0,28.5 18.1 
36 hours 24 14.5 7.0 4.0,30.0 12.5 9.8,19.0 12.9 
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A surge in LH (and FSH) was observed during the 12-hour period following 
kisspeptin administration.  
Overnight blood sampling in timed intervals was performed to determine the profile 
of hormone release in 20 of the subjects at the two highest doses of kisspeptin-54 (6.4 
or 12.8 nmol/kg; n = 10 per dose). Peak levels of plasma kisspeptin were observed 
approximately one hour after injection and subsequently fell to pre-injection levels by 
12 hours following injection.  
 
The level of serum LH reached a peak four to six hours following kisspeptin-54 
administration and decreased thereafter. Less prominent patterns of elevation were 
observed for serum FSH and oestradiol following kisspeptin-54 administration. 
Conversely the level of progesterone appeared to rise continually during the 12-hour 
period following administration of kisspeptin-54 (Figure 3.4). 
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Figure 3.4. Serum FSH, LH, oestradiol and progesterone after the administration of kisspeptin by dose 
(6.4nmol/l and 12.8nmol/l, n=10 per dose) during the 12 hours following kisspeptin-54 trigger 
administration. Results are presented as median and interquartile ranges of the serum hormone levels at 
each time interval. 
 
A release of both LH and FSH was documented with all different doses of kisspeptin. 
For the group of 1.6-3.2 nmol/kg, the mean fold increase in LH ± SEM was 5.2 ±2.4 
iu/l. For the groups of 6.4 nmol/kg and 12.8 nmol/kg the mean fold increase in LH ± 
SEM was 7.1 ±1.2 iu/l and 10.3 ±1.9 iu/l respectively. Performing a one-way 
ANOVA test to compare multiple groups using the Bonferroni correction, the trend of 
increasing LH release with higher doses of kisspeptin did not reach statistical 
significance (p= 0.35) (Figure 3.5). 
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Figure 3.5. Fold rise of LH (from just prior to trigger to 12hrs following trigger administration) for the 
different kisspeptin-54 doses. Results are presented as mean (SEM). (1.6nmol/kg, n=5; 6.4nmol/kg, 
n=24, 12.8 nmol/kg, n=24) 
 
 
Fertilisation and pregnancy 
Although the study design primarily focused on whether egg maturation is achievable 
in women injected with kisspeptin-54 during IVF treatment, we also collected and 
analysed data on the rate of egg fertilisation, biochemical pregnancy (hCG>10iu/l at 
12 days following embryo transfer), and clinical pregnancy (present fetal heart beat at 
six weeks gestation). These results are shown in Table 3.8. In total, fertilisation 
occurred in 92% of patients (defined as at least one fertilised egg), the rate of embryo 
transfer was 92%, and high-quality embryo(s) were transferred in 58% of included 
patients. The results of embryo quality are presented in Table 3.9. Furthermore 36 of 
49 patients had their embryo transfer on day five following oocyte retrieval. In 
addition the blastocyst formation rate (defined as the total number of blastocysts 
divided by the total number of 2 pronuclei zygotes formed) in these patients was 
49.4%. 31/36 patients with a day 5 embryo transfer had at least one high-quality 
embryo transferred. The biochemical pregnancy rate in our population was 40% while 
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the clinical pregnancy rate was 23% (12 of 53 treated patients). Out of the 12 women 
who achieved clinical pregnancies, ten women delivered healthy babies (eight had a 
singleton pregnancy and two women had a twin pregnancy). Two patients had 
miscarriages (at nine weeks and 12 weeks gestation respectively). 
 
The fertilisation rate can be defined as the percentage of mature (metaphase II) 
oocytes that fertilised after intracytoplasmic sperm injection. We assessed the 
fertilisation rates in the different kisspeptin dose groups (Figure 3.6). More 
specifically the mean fertilisation rates ± SEM for the 1.6-3.2 nmol/kg, 6.4 nmol/kg, 
12.8 nmol/kg groups were 40.7 ± 15.0 (%), 74.1 ± 7.4 (%) and 77.4 ± 5.7 (%) 
respectively (Figure). The one-way ANOVA test with the Bonferroni correction 
confirmed a statistically significant difference in fertilisation rates amongst the 
different kisspeptin dose groups (p= 0.032). 
 
Figure 3.6. Fertilisation rate (the percentage of mature oocytes which fertilised after intracytoplasmic 
sperm injection) for the different kisspeptin-54 dose groups. Results are presented as mean (SEM) 
(1.6nmol/kg, n=5; 6.4nmol/kg, n=24, 12.8 nmol/kg, n=24), 
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Kisspeptin-54 dose (nmol/kg) 1.6 3.2 6.4 12.8 
Patients treated 2 3 24 24 
At least one egg collected 2 3 23 24 
At least one M2 egg 2 3 22 24 
At least one fertilised egg 1 3 22 23 
Embryo transfer 1 3 22 13 
High-quality embryo transfer 0 1 15 15 
Biochemical pregnancy at 12 days 1 1 11 8 
Clinical pregnancy at 6 weeks 1 0 7 4 
Table 3.8. Patient response to IVF treatment with the use of kisspeptin as oocyte maturation trigger. 
Biochemical pregnancy has been defined as a serum hCG >10iu/l and a clinical pregnancy as the 
presence of at least one fetal heart beat on ultrasound at 6 weeks’ gestation. 
 
 
 
 
Kisspeptin-54 dose (nmol/kg) 1.6 (n=2) 3.2 (n=3) 6.4 (n=24) 12.8 (n=24) 
Fertilised oocytes 2,0 5,1,2 5.1 (2.9) 6.8 (3.8) 
Cleaved embryos (day 3) 2,0 5,1,2 5.0 (2.9) 6.3 (3.4) 
High-quality embryos at day 3 0,0 5,1,1 3.8 (2.7) 4.5 (2.7) 
Patients with day5 transfer 0 1 18 17 
Embryos at day 5  4 5.2 (2.0) 6.9 (2.3) 
High-quality embryos at day 5  3 1.9 (1.4) 2.4 (1.7) 
High quality embryos transferred 
at day 5 
 1 1.3 (0.8) 1.5 (0.7) 
Table 3.9.  Fertilisation of collected oocytes and resulting embryo quality. High-quality embryos on 
day 3 scored as 633 or better based on the NEQAS classification system. High quality embryos on day 
5 scored as 3BB or better based on the NEQAS classification system. Raw values are presented for the 
1.6 and 3.2 nmol/kg doses. Mean values and SD are presents for the 6.4 and 12.8 nmol/kg doses. 
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Adverse events 
The administration of kisspeptin-54 was tolerated well in all patients included in this 
study. This finding is in keeping with the safety profile reported in previous human 
studies (Dhillo et al, 2005; Dhillo et al, 2007; Chan et al, 2011; George et al, 2011; 
Chan et al, 2012; Young et al, 2013; Jayasena et al, 2009). Five adverse events 
occurred, which are well-recognised complications of fertility treatment and 
pregnancy (two patients had an ectopic pregnancy, one patient had a heterotopic 
pregnancy with a remaining viable intrauterine pregnancy  and two patients had a 
miscarriage after confirmation of a fetal heart beat at 6 weeks’ gestation). 
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Discussion 
Kisspeptin signaling is essential for mammalian fertility (de Roux et al, 2003; 
Seminara et al, 2003; Topaloglu et al, 2012), and exogenous administration of 
kisspeptin can potently stimulate the release of endogenous reproductive hormones in 
the mammalian species studied (see previous chapter). Kisspeptin administration may 
represent a novel method for the treatment of infertile patients. Evidence from animal 
studies suggests that kisspeptin exerts a physiological role leading to the endogenous 
LH surge, which is pivotal for ovulation. This study investigated whether a bolus 
injection of kisspeptin-54 can be used as a new method to induce oocyte maturation in 
patients undergoing IVF therapy. This study has demonstrated for the first time that a 
bolus injection of kisspeptin-54 can trigger oocyte maturation and subsequently result 
in fertilisation, implantation of the embryo at the endometrial level and –importantly- 
live birth in women with infertility undergoing IVF treatment.  
 
The primary objective of the study was to assess whether oocyte maturation was 
achievable in women administered kisspeptin-54. Oocyte maturation was assessed in 
two ways, the absolute number of mature oocytes and the proportion of collected 
oocytes that were mature (metaphase II). Mature oocytes were observed in 96% of 
study participants, and the percentage of collected oocytes that were mature, was 75-
85% following kisspeptin-54 injection at all doses administered. Circulating 
kisspeptin levels rose rapidly following kisspeptin-54 injection, and this led to a 
marked increase in LH secretion and smaller increase in FSH secretion (as expected 
from previous studies in healthy women). Kisspeptin-54 administration resulted in a 
rise in LH release sufficient to induce egg maturation in women undergoing IVF 
therapy; levels of serum LH peaked 4h post-injection, remained elevated 12h post-
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injection, and had returned to baseline 36h post-injection. Circulating levels of 
progesterone increased after kisspeptin-54 injection; a finding, which appears to be 
consistent with oocyte maturation. Consequently the data demonstrate that kisspeptin-
54 may act as a potent oocyte maturation trigger in women undergoing IVF treatment.  
The progress of patients after administration of kisspeptin-54 was followed 
prospectively. Successful embryogenesis was demonstrated for nearly all patients, 
who ovulated after the injection of kisspeptin-54 at the higher doses of 6.4nmol/kg 
and 12.8nmol/kg.  
 
Importantly twelve clinical pregnancies were documented in the current study. Until 
today ten women have successfully delivered healthy babies.  We need to 
acknowledge that the number of patients in each group was low, and various factors 
could affect pregnancy rates after oocyte maturation; it is therefore not meaningful to 
suggest that differences in pregnancy rates definitely exist between the doses of 
kisspeptin-54 used. Regardless of that, this study can importantly demonstrate for the 
first time that a healthy pregnancy in humans may result from kisspeptin-54 
administration in women undergoing in vitro fertilisation treatment. 
 
A number of ethical issues in the study design need to be acknowledged.  It would 
obviously be unethical to administer infertile patients undergoing cumbersome IVF 
cycles a placebo oocyte maturation trigger. It has been well demonstrated that the 
omission of the oocyte maturation trigger will result in failed oocyte maturation 
(termed ‘empty follicle syndrome’) (Smith et al, 2006). Furthermore, we need to 
consider that kisspeptin had never before been administered patients with infertility 
during IVF therapy prior to the commencement of this study, so the effectiveness of 
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kisspeptin-54 for this role was in essence unknown. This fact had significant ethical 
implications the process of dose escalation. As a result, a modified 3+3 trial design 
was utilised to reduce the number of patients exposed to clinically ineffective 
kisspeptin-54 doses. Consequently we may have identified kisspeptin-54 doses, which 
were proven to induce oocyte maturation in infertile women undergoing IVF 
treatment, but we cannot yet exclude that lower kisspeptin-54 doses might also induce 
oocyte maturation when used as part of an IVF treatment cycle. 
 
Kisspeptin vs. GnRH agonist to induce oocyte maturation 
The use of a GnRH agonist can provide a useful alternative treatment approach to 
hCG for oocyte maturation. GnRH agonists can stimulate the pituitary GnRH 
receptors and lead to an increased release of LH. The use of GnRH agonists for the 
purpose of triggering oocyte maturation during IVF has been linked to decreased 
OHSS rates, but has also been associated with decreased pregnancy rates (Shufaro et 
al, 2013) in comparison with hCG. Luteal phase insufficiency remains the most 
plausible mechanism behind this decrease. This insufficiency could be attributed to 
the fact that GnRH agonists may cause excessive pharmacological stimulation and 
consequently lead to desensitisation of the pituitary GnRH receptor. Kisspeptin-54 
has been implicated  in the pathway leading to the endogenous LH surge through the 
activation of the stimulate endogenous  secretion of GnRH (Goodman et al, 2007; 
Irwig et al, 2004; Gottsch et al, 2004; Messager et al, 2005).  
 
The kisspeptin pathway appears to act as a mechanism, which can be employed to 
induce oocyte maturation in patients suffering with infertility and undergoing IVF. It 
is important to stress that further studies directly comparing kisspeptin-54 with hCG 
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and GnRH agonist triggers are required to determine if the novel application of 
kisspeptin-54 as an oocyte maturation trigger can potentially result in better and safer 
outcomes for patients undergoing IVF therapy. 
   
For the purposes of clarity and transparency, the cycle characteristics and outcomes 
after the use of a bolus GnRH agonist dose as oocyte maturation trigger in the same 
setting (IVF Unit, Hammersmith Hospital) are presented below (Tables 3.10 & 3.11) 
to provide contextual information regarding how the GnRHa trigger, as currently 
practiced in the IVF Unit, has performed. No statistical comparisons were attempted 
between the two groups. 
   
According to the unit protocol, if ≥18 follicles ≥11mm are present on the day of 
trigger, a GnRH agonist trigger should be used (2mg buserelin). All patients who 
underwent a GnRH antagonist fresh IVF/ICSI cycle with the use of GnRH agonist 
trigger between October 2011 and June 2014 were included. Patients having elective 
oocyte cryopreservation, egg donors and patients having fertility preservation for 
medical reasons (e.g. cancer) were excluded.  
 
The intensive luteal phase support for these patients consisted of 100mg intramuscular 
progesterone once daily and 2mg oestradiol valerate orally twice a day until the day 
of the pregnancy test. If the pregnancy test was positive, then the intensive luteal 
phase support continued in the form of vaginal progesterone gel 9% (Crinone) once 
daily and 2mg oestradiol valerate orally twice a day until 12 weeks’ gestation.  
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Table 3.10. Cycle characteristics for patients with a GnRH agonist oocyte maturation trigger. Variables 
that are not normally distributed are presented as median (interquartile range, IQR). (E2:oestradiol, 
2PN: two pronuclei zygotes).  
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.11. Cycle outcomes. Outcomes are presented per cycle started unless stated otherwise (i.e. per 
transfer).  (OHSS: ovarian hyperstimulation syndrome) 
++ cycles cancelled because of the risk or diagnosis of OHSS 
 
Kisspeptin and ectopic pregnancy 
Cycle characteristics GnRHa group 
Follicles ≥ 11mm 23 (20-27) 
Total FSH dose 1500 (1200-2025) 
Days of stimulation 10 (9-12) 
Peak E2 (pmol/l) 9675 (6255-13168) 
Single embryo transfers (N, %) 199/351 (56.6%) 
Day 5 embryo transfers (N, %) 321/350 (91.7%) 
Oocytes collected 18 (14-25) 
Mature (M2) oocytes 15 (11-20) 
2PN zygotes 11 (7-15) 
Outcomes GnRHa group 
Positive pregnancy rate (N,%) 187/382 (48.9%) 
Positive pregnancy rate per transfer (N,%) 187/351 (53.2%) 
Clinical pregnancy rate (N,%) 119/382 (31.1%) 
Clinical pregnancy rate per transfer (N,%) 119/351 (33.9%) 
Implantation rate (N,%) 159/502 (31.6%) 
Ectopic pregnancies 
per biochemical pregnancy(N,%) 
10/187 (5.3%) 
Miscarriages per transfer (N,%) 54/351 (15.3%) 
Cancellation of embryo transfer++  (N,%) 14/382 (3.9%) 
Hospitalisation for severe OHSS 1/382 (0.26%) 
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Ectopic pregnancies are more common during assisted reproductive technology 
(ART) when compared with spontaneous pregnancies. This may be partly explained 
by the selection of women with tubal infertility, and also by alterations in tubal 
contractility as a consequence of the hormonal milieu during IVF cycles (Shufaro et 
al, 2013). Interestingly Zhao et al (2015) have recently demonstrated that the use of 
exogenous progestogens can decrease cilia beat frequency of human fallopian tubes 
and rat oviducts. In unselected IVF cycles, ectopic pregnancy is thought to occur in 2-
8.6% of pregnancies and up to 1% of pregnancies may be heterotopic (Shufaro et al, 
2013). Furthermore, ectopic pregnancy has been reported to occur in up to 11% of 
IVF pregnancies in women with tubal infertility (Chang et al, 2010; Malak et al, 
2011). In our current study 10 of the 53 women had a diagnosis of tubal infertility as 
the indication for ART. Of the three women with ectopic pregnancy, one of the 
patients may have had a higher personal risk of ectopic pregnancy, as she had been 
diagnosed with ectopic pregnancy requiring surgery in a previous pregnancy, as well 
as a pregnancy of unknown location in another pregnancy. The participant who was 
diagnosed with heterotopic pregnancy had a previous diagnosis of endometriosis, 
which was deemed mild enough for her inclusion in the study, but may have yet 
contributed to an increased personal risk of ectopic pregnancy. We would not expect 
kisspeptin treatment to confer any increase in ectopic pregnancy rate, since only a 
single injection of kisspeptin was administered and the half-life of exogenously 
administered kisspeptin is short (28 minutes) (Dhillo et al, 2005). 
 
The overall number of patients in this study is small, so the increased rate of ectopic 
pregnancy may have occurred due to statistical artefact. However, it is important to 
recognise that a higher than expected rate of ectopic pregnancy was observed, based 
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on the total number of patients in this study and the published literature. It is therefore 
possible that kisspeptin triggering has resulted in an increased rate of ectopic 
pregnancy by an as of yet unidentified mechanism; for example some dysfunctionality 
in the triggering of ovulation may have led to dyskinetic alterations in the changes in 
uterine or tubal contractility following induction of ovulation and this could have 
resulted in increased ectopic pregnancy rate.  
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Conclusion and Future Work 
This is the first human study to assess the use of kisspeptin as an oocyte maturation 
trigger in an assisted conception cycle. We have shown for the first time that 
kisspeptin can be used effectively in women undergoing IVF treatment to induce an 
endogenous LH surge, which subsequently leads to oocyte maturation, fertilisation 
and can result in a healthy baby. Kisspeptin seems to be a novel factor in assisted 
conception that could greatly influence future treatment protocols. 
 
The detailed analysis of the FSH, LH, oestradiol and progesterone levels during the 
luteal phase will allow us to gain further insight into the reproductive hormone milieu 
after the administration of kisspeptin. Future work will focus on the use of kisspeptin 
in high-risk populations for OHSS, such as women with polycystic ovarian syndrome. 
Long-term plans would also involve a direct comparison of kisspeptin with hCG or 
even more interestingly kisspeptin and GnRH agonist trigger, to assess the clinical 
and live birth rates as well as the incidence and severity of ovarian hyperstimulation 
syndrome. 
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